Cold Sore Medication Manufacturing in the US - Industry Market Research Report

Sick day: Operators are expected to contend with rising competition over the coming years

Cold Sore Medication Manufacturing

Over the five years to 2019, revenue for the Cold Sore Medication Manufacturing industry grew. Generally speaking, demand for cold sore medication is driven by broader trends such as changes in disposable income, demographic shifts and total healthcare expenditure. Changes in private health insurance coverage can also cause demand to rise or fall, as a portion of industry products include pharmaceutical treatments to treat conditions that arise from herpes simplex virus or herpes zoster virus. Still, manufacturers are expected to contend with rising competition over the next five years to 2024 from generic offerings and OTC products, which carry lower profit margins. Generics are often sold at a discounted rate as compared with brand name offerings and have been increasingly prescribed to reduce rising healthcare costs in the United States.

This industry develops and produces over-the-counter (OTC) and prescription treatments for cold sores, which are inflamed blisters in or near the mouth caused by infection from the herpes simplex virus.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.